Drug Design and Discovery Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, 110 Science Place, Saskatoon, Saskatchewan S7N 5C9, Canada.
Eur J Med Chem. 2012 May;51:193-9. doi: 10.1016/j.ejmech.2012.02.042. Epub 2012 Feb 27.
A series of bis[3,5-bis(benzylidene)-4-oxo-1-piperidinyl]amides 1 display potent cytotoxic properties towards a wide range of tumours. A number of the CC(50) and IC(50) values are in the range of 10(-8) M. Specifically, these compounds have the following important properties. First, greater toxicity was demonstrated towards certain tumours than various non-malignant cells. Second, various compounds in series 1 are toxic to a number of human colon cancer and leukaemic cells. Third, these compounds reverse P-gp mediated multidrug resistance. Various prototypic molecules such as 1a,b and 1i were identified as lead molecules for further studies. A representative lead molecule 1b induces apoptosis via internucleosomal DNA fragmentation and PARP cleavage in HSC-2 and HL-60 cells while flow cytometry revealed that this compound blocked the G2/M and S-phases in the cell cycle of human colon cancer HCT-116 cells.
一系列双[3,5-双(亚苄基)-4-氧代-1-哌啶基]酰胺 1 对多种肿瘤显示出强大的细胞毒性。许多 CC(50)和 IC(50) 值在 10(-8) M 的范围内。具体而言,这些化合物具有以下重要性质。首先,与各种非恶性细胞相比,某些肿瘤表现出更高的毒性。其次,1 系列中的各种化合物对多种人结肠癌细胞和白血病细胞有毒。第三,这些化合物逆转了 P-糖蛋白介导的多药耐药性。各种原型分子,如 1a,b 和 1i,被确定为进一步研究的先导分子。代表性的先导分子 1b 通过核小体间 DNA 片段化和 PARP 切割诱导 HSC-2 和 HL-60 细胞中的细胞凋亡,而流式细胞术显示该化合物阻止了人结肠癌细胞 HCT-116 细胞的 G2/M 和 S 期。